Role of microRNA-26b in glioma development and its mediated regulation on EphA2.
BACKGROUND
MicroRNAs (miRNAs) are short, non-coding RNAs that regulate the expression of multiple target genes. Deregulation of miRNAs is common in human tumorigenesis. Low level expression of miR-26b has been found in glioma cells. However, its underlying mechanism of action has not been determined.


RESULTS
Real-time PCR was employed to measure the expression level of miR-26b in glioma patients and cells. The level of miR-26b was inversely correlated with the grade of glioma. Ectopic expression of miR-26b inhibited the proliferation, migration and invasion of human glioma cells. A binding site for miR-26b was identified in the 3'UTR of EphA2. Over-expression of miR-26b in glioma cells repressed the endogenous level of EphA2 protein. Vasculogenic mimicry (VM) experiments were performed to further confirm the effects of miR-26b on the regulation of EphA2, and the results showed that miR-26b inhibited the VM processes which regulated by EphA2.


CONCLUSIONS
This study demonstrated that miR-26b may act as a tumor suppressor in glioma and it directly regulates EphA2 expression. EphA2 is a direct target of miR-26b, and the down-regulation of EphA2 mediated by miR-26b is dependent on the binding of miR-26b to a specific response element of microRNA in the 3'UTR region of EphA2 mRNA.
Institute of Oceanology, Chinese Academy of Sciences, Qingdao, China.
Ning
N
Wu
Xiangzhong
X
Zhao
Ming
M
Liu
Haizhou
H
Liu
Weicheng
W
Yao
Yuyan
Y
Zhang
Shousong
S
Cao
Xiukun
X
Lin
D020413:3' Untranslated Regions; D001665:Binding Sites / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D005910:Glioma / Q000209:etiology / Q000235:genetics* / Q000473:pathology; D006801:Humans; D035683:MicroRNAs / Q000502:physiology*; D012333:RNA, Messenger / Q000235:genetics; D036104:Receptor, EphA2 / Q000235:genetics*; D020218:Response Elements / Q000235:genetics; D025521:Tumor Suppressor Proteins
D020413:3' Untranslated Regions; D035683:MicroRNAs; D012333:RNA, Messenger; D036104:Receptor, EphA2; D025521:Tumor Suppressor Proteins; C528163:MIRN26 microRNA, human
Leuk Lymphoma. 2009 Jan;50(1):101-8
19148830
Prostate. 1999 Dec 1;41(4):275-80
10544301
Pathobiology. 1997;65(4):195-203
9396043
Cancer Res. 2007 Sep 15;67(18):8699-707
17875710
Mol Cell Biol. 2007 Mar;27(5):1859-67
17194750
Neoplasia. 2009 May;11(5):485-96
19412433
Cancer Biol Ther. 2008 Jul;7(7):1098-103
18443431
Oncogene. 2000 Nov 20;19(49):5614-9
11114742
J Histochem Cytochem. 2005 Aug;53(8):997-1002
15923371
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9
16166262
Genes Dev. 2009 Sep 15;23(18):2152-65
19759263
Cancer. 2009 Jun 15;115(12):2684-92
19396818
Nat Rev Cancer. 2009 Apr;9(4):293-302
19262572
Int J Cancer. 2003 Feb 20;103(5):657-63
12494475
Prostate. 2002 Feb 15;50(3):189-201
11813211
Am J Pathol. 2003 Apr;162(4):1037-42
12651595
Mol Cancer Res. 2005 Oct;3(10):541-51
16254188
Science. 2010 Mar 12;327(5971):1380-5
20223987
Cell. 2005 Mar 11;120(5):635-47
15766527
Anticancer Res. 2005 Jul-Aug;25(4):2943-50
16080548
Nat Genet. 2007 May;39(5):582-3
17460676
Cancer Lett. 2007 Sep 8;254(2):157-64
17306454
Melanoma Res. 2000 Oct;10(5):401-11
11095400
Surg Neurol. 2008 Dec;70(6):562-8; discussion 568-9
18614215
Am J Pathol. 1999 Sep;155(3):739-52
10487832
Am J Physiol Lung Cell Mol Physiol. 2009 Nov;297(5):L856-63
19684201
Nucleic Acids Res. 2005 Nov 27;33(20):e179
16314309
Cancer Biol Ther. 2008 May;7(5):758-66
18376140
Cancer Res. 2001 Apr 15;61(8):3250-5
11309274
Dev Dyn. 2007 Dec;236(12):3283-96
17557303
Oncogene. 2000 Dec 7;19(52):6043-52
11146556
Clin Cancer Res. 2004 Aug 1;10(15):5145-50
15297418
Cancer Res. 2007 Mar 15;67(6):2456-68
17363563
Cell. 2009 Dec 11;139(6):1096-108
20005803
Cancer Res. 2002 Jan 15;62(2):560-6
11809710
Methods. 2001 Dec;25(4):402-8
11846609
Genes Dev. 2009 Aug 1;23(15):1743-8
19574298
Dis Colon Rectum. 2009 Dec;52(12):2028-35
19934926
Mol Cancer Res. 2008 Dec;6(12):1795-806
19074825
Cancer Res. 2001 Mar 1;61(5):2301-6
11280802
Tumour Biol. 2007;28(3):165-72
17519535
Nat Rev Cancer. 2006 Nov;6(11):857-66
17060945